Amgen v Sanofi-Aventis Deutschland (CFI, 16 August 2023)

Date	16 August 2023
Court	CFI
Division	Munich (DE) Local Division
Type of action	Infringement Action
Case number(s)	UPC_CFI_14/2023
Registry reference	ORD_562104/2023 · UPC_CFI_14/2023
Parties	Amgen Inc. v. Sanofi-Aventis Deutschland GmbH

Summary pending review. Official UPC registry metadata imported on 24 September 2026.

Official decision (PDF) · UPC registry entry

Case timeline

17 July 2023 : Amgen v Sanofi-Aventis Deutschland (CFI, 17 July 2023) ORD_551192/2023 · UPC_CFI_14/2023
28 July 2023 : Amgen v Sanofi-Aventis Deutschland (CFI, 28 July 2023) ORD_556750/2023 · UPC_CFI_14/2023
17 August 2023 : Amgen v Sanofi-Aventis Deutschland (CFI, 17 August 2023) ORD562104/2023 · UPC_CFI_14/2023
17 August 2023 : Sanofi-Aventis Deutschland v Amgen (CFI, 17 August 2023) ORD_562104/2023 · UPC_CFI_14/2023
29 August 2023 : Amgen v Sanofi-Aventis Deutschland (CFI, 29 August 2023) ORD_566193/2023 · UPC_CFI_14/2023
3 November 2023 : Amgen v Sanofi-Aventis Deutschland (CFI, 3 November 2023) ORD_584907/2023 · UPC_CFI14/2023
2 January 2024 : Amgen v Sanofi-Aventis Deutschland (CFI, UPC_CFI_14/2023, ORD_597730/2023, 2 January 2024) ORD_597730/2023 · UPC_CFI14/2023
2 January 2024 : Amgen v Sanofi-Aventis Deutschland (CFI, UPC_CFI_14/2023, ORD_597730/2023, 2 January 2024, doc. 2) ACT_459916/2023 · ORD_597730/2023 · UPC_CFI_14/2023
2 January 2024 : Amgen v Sanofi-Aventis Deutschland (CFI, UPC_CFI_14/2023, ORD_597730/2023, 2 January 2024, doc. 3) ACT_459916/2023 · ORD_597730/2023 · UPC_CFI_14/2023
2 February 2024 : Amgen v Sanofi-Aventis Deutschland (CFI, 2 February 2024) ACT_459916/2023 · ORD_392/2024 · UPC_CFI_14/2023
24 February 2024 : Sanofi v Amgen (CFI, 24 February 2024) ACT_459505/2023andCC_586764/2023 · ORD_10396/2024 · ORD_10398/2024 · UPC_CFI_1/2023 · UPC_CFI_14/2023

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

English summary awaiting review. Read the French case note.

Source and translations

Official source: Unified Patent Court registry link recorded in the record
Original language: not recorded
Translation available: no translation recorded the firm’s French record is a summary, not a translation
Date checked: not recorded

Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

UPC_CFI_14/2023 official number

Follow this case

Parties

defendantSanofi-Aventis Deutschland GmbH28 decisions in the corpus Follow this party
claimantAmgen Inc.24 decisions in the corpus Follow this party

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

17 July 2023 Amgen v Sanofi-Aventis Deutschland (CFI, 17 July 2023) Infringement Action · UPC_CFI_14/2023
Le juge rapporteur disjoint la procédure contre Regeneron, non encore signifiée, pour ne pas retarder l'instance contre les sociétés Sanofi, et partage par moitié les frais de justice.
28 July 2023 Amgen v Sanofi-Aventis Deutschland (CFI, 28 July 2023) Infringement Action · UPC_CFI_14/2023
La procédure contre Regeneron n'est pas disjointe, Amgen ayant retiré sa demande après la signification. L'ordonnance provisoire du 17 juillet 2023 devient sans objet.
16 August 2023 Amgen v Sanofi-Aventis Deutschland (CFI, 16 August 2023) Infringement Action · UPC_CFI_14/2023
17 August 2023 Amgen v Sanofi-Aventis Deutschland (CFI, 17 August 2023) Infringement Action · UPC_CFI_14/2023
Le juge rapporteur dispense exceptionnellement les parties de réitérer les demandes déposées dans de mauvais circuits, réserve un circuit unique aux questions de délais et fixe au 22 août 2023 le terme des observations.
17 August 2023 Sanofi-Aventis Deutschland v Amgen (CFI, 17 August 2023) Generic Order · UPC_CFI_14/2023
29 August 2023 Amgen v Sanofi-Aventis Deutschland (CFI, 29 August 2023) Infringement Action · UPC_CFI_14/2023
La division locale juge le mémoire en demande complet et valablement signifié malgré le téléversement ultérieur des pièces annoncées, refuse en principe toute prorogation, mais aligne à titre exceptionnel le délai de défense de tous les défendeurs au 17 octobre 2023.
3 November 2023 Amgen v Sanofi-Aventis Deutschland (CFI, 3 November 2023) Infringement Action · UPC_CFI_14/2023
La langue de procédure passe de l'allemand à l'anglais, langue de délivrance du brevet, toutes les parties et la formation y consentant. Amgen traduit son mémoire introductif sous deux mois.
2 January 2024 Amgen v Sanofi-Aventis Deutschland (CFI, UPC_CFI_14/2023, ORD_597730/2023, 2 January 2024) Infringement Action · UPC_CFI_14/2023
Le juge rapporteur proroge au 8 janvier 2024 le délai accordé aux défenderesses pour commenter les dates provisoires de la conférence intermédiaire et de l'audience.
2 January 2024 Amgen v Sanofi-Aventis Deutschland (CFI, UPC_CFI_14/2023, ORD_597730/2023, 2 January 2024, doc. 2) Infringement Action · UPC_CFI_14/2023
2 January 2024 Amgen v Sanofi-Aventis Deutschland (CFI, UPC_CFI_14/2023, ORD_597730/2023, 2 January 2024, doc. 3) Infringement Action · UPC_CFI_14/2023
2 February 2024 Amgen v Sanofi-Aventis Deutschland (CFI, 2 February 2024) Infringement Action · UPC_CFI_14/2023
La division locale de Munich renvoie la demande reconventionnelle en nullité de Regeneron à la division centrale et poursuit l'action en contrefaçon d'Amgen, en se réservant de la suspendre ultérieurement.
24 February 2024 Sanofi v Amgen (CFI, 24 February 2024) Revocation Action · UPC_CFI_14/2023
L'action en nullité de Sanofi et la demande reconventionnelle en nullité de Regeneron contre le brevet d'Amgen sont instruites conjointement en vue d'une audience le 4 juin 2024, la valeur de chaque action étant fixée à 100 millions d'euros.

What the record states

Nature of the act: Infringement Action
Outcome (Dhenne Avocats summary): Le juge rapporteur dispense exceptionnellement les parties de réitérer les demandes déposées dans de mauvais circuits, fixe au 21 août 2023 le terme des observations et réserve un circuit unique aux délais et à l'audition conjointe.
Appeal: No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance: First-instance decision, whether it has become final is not recorded.

Patents mentioned

EP 3 666 797 mentioned in: Dhenne Avocats analysis Follow this patent

Related decisions cited in the analyses

Sanofi v Amgen (CFI, 24 February 2024) cited in this record
Amgen v Sanofi-Aventis Deutschland (CFI, 2 February 2024) cited in this record
Amgen v Sanofi-Aventis Deutschland (CFI, UPC_CFI_14/2023, ORD_597730/2023, 2 January 2024) cited in this record
Amgen v Sanofi-Aventis Deutschland (CFI, UPC_CFI_14/2023, ORD_597730/2023, 2 January 2024, doc. 2) cited in this record
Amgen v Sanofi-Aventis Deutschland (CFI, UPC_CFI_14/2023, ORD_597730/2023, 2 January 2024, doc. 3) cited in this record
Amgen v Sanofi-Aventis Deutschland (CFI, 3 November 2023) cited in this record
Amgen v Sanofi-Aventis Deutschland (CFI, 29 August 2023) cited in this record
Amgen v Sanofi-Aventis Deutschland (CFI, 17 August 2023) cited in this record
Sanofi-Aventis Deutschland v Amgen (CFI, 17 August 2023) cited in this record
Amgen v Sanofi-Aventis Deutschland (CFI, 28 July 2023) cited in this record
Amgen v Sanofi-Aventis Deutschland (CFI, 17 July 2023) cited in this record

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

Publication	Role in the dispute	Family	Standard and declaration	Pool	Sources
`EP 3 666 797` Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) recorded proprietor: Amgen Inc	Mentioned in the analysis (role not qualified) Also mentioned in 21 other decision(s): Amgen v Sanofi-Aventis Deutschland (CoA, 25 November 2025) · Sanofi-Aventis Deutschland v Amgen (CFI, 16 July 2024) · Regeneron Pharmaceuticals v Amgen (CFI, 16 July 2024) · SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 25 March 2026) · SANOFI-AVENTIS DEUTSCHLAND v AMGEN (CoA, 18 February 2026) · Dehns v Regeneron Pharmaceuticals (CFI, 22 October 2024) · Sanofi-Aventis Deutschland v Amgen (CFI, ORD_47230/2024, 22 October 20 · Sanofi-Aventis Deutschland v Amgen (CFI, ORD_47238/2024, 22 October 20	not recorded	not recorded	not recorded	Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis

The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.